Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration

• Main Authors: Manuela Basso (Author), Saravanan S.Karuppagounder (Author), Jürgen Rohr (Author), Rajiv R. Ratan (Author), Jill Berlin (Author), Sama F. Sleiman (Author)
• Format: Book
• Published: MDPI AG, 2011-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Mithramycin A (MTM) and histone deacetylase inhibitors (HDACi) are effective therapeutic agents for cancer and neurodegenerative diseases. MTM is a FDA approved aureolic acid-type antibiotic that binds to GC-rich DNA sequences and interferes with Sp1 transcription factor binding to its target sites...